On the other hand, the HER2-low status should not be confused with the intratumor heterogeneity phenomenon [77]; the latter event may be generally responsible for a different positive response to targeted therapy in tissue microarrays (TMAs) of BC [77]. This evidence concerns the gene ERBB2 and breast cancer.